0001829126-22-011008.txt : 20220516 0001829126-22-011008.hdr.sgml : 20220516 20220513190109 ACCESSION NUMBER: 0001829126-22-011008 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 33 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220516 DATE AS OF CHANGE: 20220513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMERIGUARD SECURITY SERVICES, INC. CENTRAL INDEX KEY: 0001514443 STANDARD INDUSTRIAL CLASSIFICATION: INSURANCE AGENTS BROKERS & SERVICES [6411] IRS NUMBER: 990363866 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-173039 FILM NUMBER: 22924614 BUSINESS ADDRESS: STREET 1: 5470 W. SPRUCE AVENUE , SUITE 102 CITY: FRESNO STATE: CA ZIP: 93722 BUSINESS PHONE: 559-271-5984 MAIL ADDRESS: STREET 1: 5470 W. SPRUCE AVENUE , SUITE 102 CITY: FRESNO STATE: CA ZIP: 93722 FORMER COMPANY: FORMER CONFORMED NAME: HEALTH REVENUE ASSURANCE HOLDINGS, INC. DATE OF NAME CHANGE: 20120423 FORMER COMPANY: FORMER CONFORMED NAME: HEALTH REVENEUE ASSURANCE HOLDINGS, INC. DATE OF NAME CHANGE: 20120420 FORMER COMPANY: FORMER CONFORMED NAME: ANVEX INTERNATIONAL, INC. DATE OF NAME CHANGE: 20110303 10-Q 1 ameriguardsecurity_10q.htm 10-Q
0001514443 false 12/31 2022 Q1 0001514443 2022-01-01 2022-03-31 0001514443 2022-05-08 0001514443 2022-03-31 0001514443 2021-12-31 0001514443 2021-01-01 2021-03-31 0001514443 hraad:SeriesAOnePreferredStockMember 2020-12-31 0001514443 us-gaap:CommonStockMember 2020-12-31 0001514443 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001514443 us-gaap:RetainedEarningsMember 2020-12-31 0001514443 2020-12-31 0001514443 hraad:SeriesAOnePreferredStockMember 2021-03-31 0001514443 us-gaap:CommonStockMember 2021-03-31 0001514443 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001514443 us-gaap:RetainedEarningsMember 2021-03-31 0001514443 2021-03-31 0001514443 hraad:SeriesAOnePreferredStockMember 2021-06-30 0001514443 us-gaap:CommonStockMember 2021-06-30 0001514443 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001514443 us-gaap:RetainedEarningsMember 2021-06-30 0001514443 2021-06-30 0001514443 hraad:SeriesAOnePreferredStockMember 2021-09-30 0001514443 us-gaap:CommonStockMember 2021-09-30 0001514443 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001514443 us-gaap:RetainedEarningsMember 2021-09-30 0001514443 2021-09-30 0001514443 hraad:SeriesAOnePreferredStockMember 2021-12-31 0001514443 us-gaap:CommonStockMember 2021-12-31 0001514443 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001514443 us-gaap:RetainedEarningsMember 2021-12-31 0001514443 hraad:SeriesAOnePreferredStockMember 2021-01-01 2021-03-31 0001514443 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001514443 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001514443 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001514443 hraad:SeriesAOnePreferredStockMember 2021-04-01 2021-06-30 0001514443 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001514443 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001514443 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001514443 2021-04-01 2021-06-30 0001514443 hraad:SeriesAOnePreferredStockMember 2021-07-01 2021-09-30 0001514443 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001514443 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001514443 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001514443 2021-07-01 2021-09-30 0001514443 hraad:SeriesAOnePreferredStockMember 2021-10-01 2021-12-31 0001514443 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0001514443 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0001514443 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0001514443 2021-10-01 2021-12-31 0001514443 hraad:SeriesAOnePreferredStockMember 2022-01-01 2022-03-31 0001514443 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001514443 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001514443 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001514443 hraad:SeriesAOnePreferredStockMember 2022-03-31 0001514443 us-gaap:CommonStockMember 2022-03-31 0001514443 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001514443 us-gaap:RetainedEarningsMember 2022-03-31 0001514443 hraad:CustodianVenturesMember 2021-09-08 0001514443 2021-09-08 0001514443 2021-09-01 2021-09-08 0001514443 2022-03-01 2022-03-11 0001514443 2022-03-11 0001514443 hraad:CustodianVenturesLLCMember 2021-09-01 2021-09-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2022

 

Or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ______ to ______

 

Commission file number 333-173039

 

AMERIGUARD SECURITY SERVICES, INC.

 

(Exact name of registrant as specified in its charter)

 

HEALTH REVENUE ASSURANCE HOLDINGS, INC.

(Prior name)

 

Nevada   99-0363866

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

5470 W. Spruce Avenue, Suite 102    
Fresno, CA   93722
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code (559) 271-5984

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of exchange on which registered
N/A   N/A   N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☐ Yes   ☒ No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☐ Yes   ☒ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated Filer Smaller reporting company
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act.) ☒ Yes   ☐ No

 

The number of shares outstanding of the registrant’s common stock as of May 8,2022 was 3,417,302 shares.

 

 

 

 

 

 

TABLE OF CONTENTS

 

    PAGE
Part I – FINANCIAL INFORMATION   1
     
Item 1. Financial Statements (unaudited)   2
       
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations   10
       
Item 3. Quantitative and Qualitative Disclosures about Market Risk   11
       
Item 4. Controls and Procedures   11
       
Part II – OTHER INFORMATION   13
     
Item 1. Legal Proceedings   13
       
Item 1A. Risk Factors   13
       
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds   13
       
Item 3. Defaults Upon Senior Securities   13
       
Item 4. Mine Safety Disclosures   13
       
Item 5. Other Information   13
       
Item 6. Exhibits   14
       
SIGNATURES   15

 

i

 

 

PART I - FINANCIAL INFORMATION

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

Information contained in this quarterly report on Form 10-Q contains “forward-looking statements.” These forward-looking statements are contained principally in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and are generally identifiable by use of the words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend” or “project” or the negative of these words or other variations on these words or comparable terminology. The forward-looking statements herein represent our expectations, beliefs, plans, intentions or strategies concerning future events, including, but not limited to: our ability to consummate the business combination, as such term is defined below; the continued services of the Officer as such term is defined below; our future financial performance; the continuation of historical trends; the sufficiency of our resources in funding our operations; our intention to engage in mergers and acquisitions; and our liquidity and capital needs. Our forward-looking statements are based on assumptions that may be incorrect, and there can be no assurance that any projections or other expectations included in any forward-looking statements will come to pass. Moreover, our forward-looking statements are subject to various known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from future results, performance or achievements expressed or implied by any forward-looking statements. These risks, uncertainties and other factors include but are not limited to: the risks of limited management, labor, and financial resources; our ability to establish and maintain adequate internal controls; our ability to develop and maintain a market in our securities; and our ability obtain financing, if and when needed, on terms that are acceptable. Except as required by applicable laws, we undertake no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.

 

As used in this quarterly report on Form 10-Q, “we”, “our”, “us” and the “Company” refer to Ameriguard Security Services, Inc. a Nevada corporation unless the context requires otherwise.

 

1

 

 

Item 1. Financial Statements.

 

Index to Financial Statements (unaudited)

 

  Page
Financial Statements (unaudited):    
     
Balance Sheets as of March 31, 2022, (unaudited) and December 31, 2021   3
     
Statements of Operations for the Three Months Ended March 31, 2022 and 2021 (unaudited)   4
     
Statement of Stockholders’ Deficit for the Three Months Ended March 31, 2022 and 2021 (unaudited)   5
     
Statements of Cash Flows for the Three months Ended March 31, 2022 and 2021 (unaudited)   6
     
Notes to Financial Statements March 31, 2022 (unaudited)   7

 

2

 

 

AMERIGUARD SECURITY SERVICES, INC.
(formerly HEALTH REVENUE ASSURANCE HOLDINGS, INC.)
BALANCE SHEETS

 

           
   March 31,   December 31, 
   2022   2021 
   (Unaudited)     
ASSETS          
Current Assets          
Cash  $-   $- 
Total Current Assets   -    - 
           
TOTAL ASSETS  $-   $- 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIT          
LIABILITIES          
Current Liabilities          
Due to related party  $29,776   $10,596 
Total Current Liabilities   29,776    10,596 
           
STOCKHOLDERS’ DEFICIT          
Series A-1 Preferred Stock, par value $0.001 25,000,000 shares authorized, 10,000,000 shares issued and outstanding at March 31, 2021 and December 31, 2021, respectively   10,000    10,000 
Common stock, par value $0.001, 500,000,000 shares authorized, 3,417,302 (post-split) and 68,346,042 (pre-split) shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively   68,346    68,346 
Additional paid-in capital   9,976,045    9,976,045 
Accumulated deficit   (10,084,167)   (10,064,987)
Total Stockholders’ Deficit   (29,776)   (10,596)
           
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT  $-   $- 

 

The accompanying unaudited notes are an integral part of these unaudited financial statements.

 

3

 

 

AMERIGUARD SECURITY SERVICES, INC.
(formerly HEALTH REVENUE ASSURANCE HOLDINGS, INC.)
STATEMENT OF OPERATIONS (unaudited)

 

           
   For the
Three Months Ended
 
   March 31,   March 31, 
   2022   2021 
Revenue  $-   $- 
Total Revenue   -    - 
           
Expenses          
General and administrative expenses   2,980    5,183 
Professional fees   16,200    - 
Total Operating Expenses   19,180    5,183 
           
Net Income (Loss)  $(19,180)  $(5,183)
           
Net Income (Loss)          
Basic and diluted earnings per share  $(0.01)  $(0.01)
           
Weighted average number of common shares outstanding - basic and diluted   3,417,302    68,346,042 

 

The accompanying unaudited notes are an integral part of these unaudited financial statements.

 

4

 

 

AMERIGUARD SECURITY SERVICES, INC.

(formerly HEALTH REVENUE ASSURANCE HOLDINGS, INC.)

STATEMENTS OF STOCKHOLDERS’ DEFICIT (unaudited)
For the Three Months Ended March 31, 2022 and the Year Ended December 31, 2021

 

                                    
   Series A-1           Additional       Total 
   Preferred Stock   Common Stock   Paid-In   Accumulated   Stockholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   Deficit 
Balance at December 31, 2020   10,000,000    10,000    68,346,042    68,346    9,939,684    (10,043,670)   (25,640)
Net loss for the period ended March 31, 2021   -    -    -    -    -    (5,183)   (5,183)
Balance at March 31, 2021   10,000,000    10,000    68,346,042    68,346    9,939,684    (10,048,853)   (30,823)
Net loss for the period ended June 30, 2021   -    -    -    -    -    (2,847)   (2,847)
Balance at June 30, 2021   10,000,000    10,000    68,346,042    68,346    9,939,684    (10,051,700)   (33,670)
Forgivness of related party debt   -    -    -    -    36,361    -    36,361 
Net loss for the period ended September 30, 2021   -    -    -    -    -    (9,347)   (9,347)
Balance at September 30, 2021   10,000,000    10,000    68,346,042    68,346    36,361    (10,061,047)   (6,656)
Net loss for the period ended December 31, 2021   -    -    -    -    -    (3,940)   (3,940)
Balance at December 31, 2021   10,000,000    10,000    68,346,042    68,346    9,976,045    (10,064,987)   (10,596)
Reverse Split of Common Stock 1 for 20             3,417,302    68,346                
Net loss for the period ended March 31, 2022   -    -    -    -    -    (19,180)   (19,180)
Balance at March 31, 2022   10,000,000    10,000    3,417,302    68,346    9,976,045    (10,084,167)   (29,776)

 

The accompanying unaudited notes are an integral part of these unaudited financial statements.

 

5

 

 

AMERIGUARD SECURITY SERVICES, INC.
(formerly HEALTH REVENUE ASSURANCE HOLDINGS, INC.)
STATEMENT OF CASH FLOWS (unaudited)

 

           
  

For the

Three Months Ended
March 31,

 
   2022   2021 
Cash Flow from Operating Activities          
Net Income (Loss)  $(19,180)  $(5,183)
Adjustments to reconcile net loss to net cash used in operating activities:          
Increase (Decrease) in operating assets and liabilities:          
Due to related party   19,180    5,183 
Net Cash used in operating activities   -    - 
           
Cash Flows from Financing Activities   -    - 
Net Cash provided by financing activities   -    - 
           
Net increase (decrease) in cash   -    - 
Cash at beginning of period   -    - 
Cash at end of period  $-   $- 
           
Supplemental Disclosure of Interest and Income Taxes Paid:          
Interest paid during the period  $-   $- 
Income taxes paid during the period  $-   $- 

 

The accompanying unaudited notes are an integral part of these unaudited financial statements.

 

6

 

 

AMERIGUARD SECURITY SERVICES, INC.
(formerly HEALTH REVENUE ASSURANCE HOLDINGS, INC.)
NOTES TO FINANCIAL STATEMENTS

March 31, 2022 (unaudited)

 

1 – NATURE OF BUSINESS AND GOING CONCERN

 

Overview

 

Ameriguard Security Services, Inc. (formerly Health Revenue Assurance Holdings, Inc). (the “Company”) intended to become a provider of revenue cycle services to a broad range of healthcare providers.

 

On February 10, 2012, HRAA entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Health Revenue Assurance Holdings, Inc. (formerly known as Anvex International, Inc., “HRAH”), a Nevada company, and its wholly-owned subsidiary Health Revenue Acquisition Corporation (“Acquisition Sub”), which was treated for accounting purposes as a reverse recapitalization with HRAA, considered the accounting acquirer.

 

The Company has been dormant since August 2014.

 

On July 14, 2020, as a result of a custodianship in Clark County, Nevada, Case Number: A816259, Custodian Ventures LLC (“Custodian”) was appointed Custodian of the Company.

 

On July 15, 2020, Custodian appointed David Lazar as the Company’s Chief Executive Officer, President, Secretary, Chief Financial Officer, Chief Executive Officer and Chairman of the Board of Directors.

 

On September 8, 2021, as a result of a private stock purchase agreement, 10,000,000 shares of Series A-1 Preferred Stock, $0.001 par value per share (the “Shares”) of the Company, were transferred from Custodian Ventures, LLC to Ameriguard Security Services, Inc. California corporation. As a result, the Ameriguard Security Services, Inc. California corporation, became holder of approximately 91% of the voting rights of the issued and outstanding share capital of the Company on a fully-diluted basis of the Company, and became the controlling shareholder. The consideration paid for the Shares was $450,000. In connection with the transaction, David Lazar has forgiven the Company from all debts owed to him and/or Custodian Ventures, LLC.

 

On September 8, 2021, the Company accepted the resignations from David Lazar as the Company’s Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and as a Member of the Board of Directors. Effective on the same date to fill the vacancies created by Mr. Lazar’s resignations, the Company appointed Lawrence Garcia as the Company’s President, CEO, CFO, Treasurer, Secretary, and Chairman of the Board of Directors. These resignations are in connection with the consummation of the private stock purchase agreement and was not the result of any disagreement with Company on any matter relating to Company’s operations, policies or practices.

 

On March 11, 2022, the Company, amended its articles of incorporation to change its name to Ameriguard Security Services, Inc. from Health Revenue Assurance Holdings, Inc. The name was deemed effective by FINRA on March 17, 2022.

 

Going Concern

 

The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the twelve months following the date of these financial statements. As of March 31, 2022, the Company had no cash and an accumulated deficit of $10,084,167.

 

Because the Company does not expect that existing operational cash flow will be sufficient to fund presently anticipated operations, this raises substantial doubt about the Company’s ability to continue as a going concern. Therefore, the Company will need to raise additional funds and is currently exploring alternative sources of financing. Recently the Company is being funded by Ameriguard Security Services, Inc., California corporation which has extended interest-free demand loans to the Company. Historically, the Company raised capital through private placements, to finance working capital needs and may attempt to raise capital through the sale of common stock or other securities and obtaining some short-term loans. The Company will be required to continue to so until its operations become profitable. Also, the Company has, in the past, paid for consulting services with its common stock to maximize working capital, and intends to continue this practice where feasible.

 

7

 

 

2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying financial statements have been prepared in accordance with the Financial Accounting Standards Board (“FASB”) “FASB Accounting Standard Codification™” (the “Codification”) which is the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) in the United States.

 

Management’s Representation of Interim Financial Statements

 

The accompanying unaudited financial statements have been prepared by the Company without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The Company uses the same accounting policies in preparing quarterly and annual financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted as allowed by such rules and regulations, and management believes that the disclosures are adequate to make the information presented not misleading. These financial statements include all the adjustments, which in the opinion of management are necessary to a fair presentation of financial position and results of operations. All such adjustments are of a normal and recurring nature. Interim results are not necessarily indicative of results for a full year. These financial statements should be read in conjunction with the audited financial statements and notes thereto on December 31, 2021, as presented in the Company’s Annual Report on Form 10-K.

 

Use of Estimates

 

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to income taxes and contingencies. The Company bases its estimates on historical experience, known or expected trends, and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.

 

Cash and cash equivalents

 

The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. The Company had no cash on hand as of March 31, 2022, and December 31, 2021, respectively.

 

Income taxes

 

The Company accounts for income taxes under FASB ASC 740, “Accounting for Income Taxes”. Under FASB ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under FASB ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. FASB ASC 740-10-05, “Accounting for Uncertainty in Income Taxes” prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities.

 

The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. The Company assesses the validity of its conclusions regarding uncertain tax positions quarterly to determine if facts or circumstances have arisen that might cause it to change its judgment regarding the likelihood of a tax position’s sustainability under audit.

 

8

 

 

Net Loss per Share

 

Net loss per common share is computed by dividing net loss by the weighted average common shares outstanding during the period as defined by Financial Accounting Standards, ASC Topic 260, “Earnings per Share.” Basic earnings per common share (“EPS”) calculations are determined by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding.

 

Recent Accounting Pronouncements

 

There are no recent accounting pronouncements that impact the Company’s operations.

 

3 – EQUITY

 

Common Stock

 

On March 11, 2022, the Company amended its articles of incorporation to reverse split its Common Stock at a rate of one-for-20, which was declared effective by FINRA on March 17, 2022. The Common Stock was reverse split to post-split 3,417,302 shares from pre-split 68,346,042 common shares.

 

The Company has authorized 500,000,000 shares of $0.001 par value, Common Stock. As of March 31, 2022 and December 31, 2021, there were 3,417,302 (pre-split 68,346,042) and 68,346,042 (post-split 3,417,302) shares of Common Stock issued and outstanding, respectively.

 

Preferred Stock

 

On November 16, 2020, the Company designated, out of the Twenty-five Million (25,000,000) shares of preferred stock, par value $0.001 per share, of Series A-1 Preferred Stock, consisting of Ten Million (10,000,000) shares, which are convertible to common stock at the conversion ratio of 72 shares of common stock for each share of preferred stock. These shares were awarded to Custodian Ventures, managed by former officer and director David Lazar, for services performed for the Company. These shares were valued at par value assuming all of the preferred shares were converted to common stock, or $720,000 which was recorded as stock-based compensation.

 

On September 8, 2021, in a private transaction Custodian Ventures LLC sold its Series A-1 Preferred Stock to Ameriguard Security Services, Inc., California corporation. The officer and control person of Ameriguard Security Services, Inc., California corporation is Lawrence Garcia, the Company’s President, CEO, CFO, Treasurer, Secretary, and Chairman of the Board of Directors.

 

As of March 31, 2022 and December 31, 2021, there were 10,000,000 shares of Series A-1 Preferred Stock issued and outstanding, respectively.

 

4 – DUE TO RELATED PARTY

 

As of September 8, 2021, the Company had a due to related party Custodian Ventures LLC, of which former officer and director David Lazar is a managing member, totaling $36,361. On September 8, 2021, the $36,361 was forgiven in full by Custodian Ventures LLC and the Company recorded the resulting gain as additional paid-in capital.

 

During the quarter ended March 31, 2022, Ameriguard Security Services, Inc., California corporation paid expenses on behalf of the Company totaling $19,180. As of March 31, 2022, the Company had a balance due to related party totaling $29,776.

 

5 – COMMITMENTS AND CONTINGENCIES

 

The Company did not have any contractual commitments as of March 31,2022, and December 31, 2021, respectively.

 

6 – SUBSEQUENT EVENTS

 

In accordance with SFAS 165 (ASC 855-10) management has performed an evaluation of subsequent events through the date that the financial statements were available to be issued and has determined that it does not have any material subsequent events to disclose in these financial statements.

 

9

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

Organizational History of the Company and Overview

 

Plan of Operation

 

We are pursuing a business combination with Ameriguard Security Services, Inc., California corporation. To date we have no signed definitive agreement, have not submitted the terms of the proposed transaction to appropriate regulatory agencies for approval and have not determined the terms of any agreement. If a business combination is consummated with Ameriguard Security Services, Inc., California corporation, our Company will cease to be a shell company (as defined in Rule 12b-2 of the Exchange Act). We will be an operating company engaged in providing security services.

 

The Company has no operations from a continuing business other than the expenditures related to running the Company and has no revenue from continuing operations as of the date of this Report.

 

In addition to pursuing the business combination, as noted in the plan of operation, management intends to explore and identify business opportunities within the U.S., including a potential acquisition of an operating entity through a reverse merger, asset purchase or similar transaction. Our ability to effectively identify, develop and implement a viable plan for our business may be hindered by risks and uncertainties which are beyond our control, including without limitation, the continued negative effects of the coronavirus pandemic on the U.S. and global economies. For more information see our 2021 Form 10-K.

 

We do not currently engage in any business activities that provide revenue or cash flow. During the next 12-month period we anticipate incurring costs in connection with investigating, evaluating, and negotiating potential business combinations, filing SEC reports, and consummating an acquisition of an operating business.

 

Given our limited capital resources, we may consider a business combination with an entity which has recently commenced operations, is a developing company or is otherwise in need of additional funds for the development of new products or services or expansion into new markets, is an established business experiencing financial or operating difficulties and is in need of additional capital. Alternatively, a business combination may involve the acquisition of, or merger with, an entity which desires access to the U.S. capital markets.

 

Other than our pursuit of combination, as noted in our plan of operation, as of the date of this Report, our management has not had any discussions with any representative of any other entity regarding a potential business combination. Any target business that is selected may be financially unstable or in the early stages of development. In such event, we expect to be subject to numerous risks inherent in the business and operations of a financially unstable or early-stage entity. In addition, we may consummate a business combination with an entity in an industry characterized by a high level of risk or in which our management has limited experience, and, although our management will endeavor to evaluate the risks inherent in a particular target business, there can be no assurance that we will properly ascertain or assess all significant risks.

 

Our management anticipates that we will likely only be able to effect one business combination due to our limited capital. This lack of diversification will likely pose a substantial risk in investing in the Company for the indefinite future because it will not permit us to offset potential losses from one venture or operating territory against gains from another. The risks we face will likely be heightened to the extent we acquire a business operating in a single industry or geographical region.

 

We anticipate that the selection of a business combination will be a complex and risk-prone process. Because of general economic conditions, including unfavorable conditions caused by the coronavirus pandemic, rapid technological advances being made in some industries and shortages of available capital, management believes that there are a number of firms seeking business opportunities at this time at discounted rates with which we will compete. We expect that any potentially available business combinations may appear in a variety of different industries or regions and at various stages of development, all of which will likely render the task of comparative investigation and analysis of such business opportunities extremely difficult and complicated. Once we have developed and begun to implement our business plan, management intends to fund our working capital requirements through a combination of our existing funds and future issuances of debt or equity securities. Our working capital requirements are expected to increase in line with the implementation of a business plan and commencement of operations.

 

10

 

 

Based upon our current operations, we do not have sufficient working capital to fund our operations over the next 12 months. If we are able to close a reverse merger, it is likely we will need capital as a condition of closing that acquisition. Because of the uncertainties, we cannot be certain as to how much capital we need to raise or the type of securities we will be required to issue. In connection with a reverse merger, we will be required to issue a controlling block of our securities to the target’s shareholders which will be very dilutive.

 

Additional issuances of equity or convertible debt securities will result in dilution to our current shareholders. Further, such securities might have rights, preferences, or privileges senior to our Common Stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, we may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict our business operations.

 

We anticipate that we will incur operating losses in the next 12 months, principally costs related to our being obligated to file reports with the SEC. Our prospects must be considered in light of the risks, expenses and difficulties frequently encountered by companies in their early stage of development. Such risks for us include, but are not limited to, an evolving and unpredictable business model, recognition of revenue sources, and the management of growth. To address these risks, we must, among other things, develop, implement, and successfully execute our business and marketing strategy, respond to competitive developments, and attract, retain, and motivate qualified personnel. There can be no assurance that we will be successful in addressing such risks, and the failure to do so could have a material adverse effect on our business prospects, financial condition, and results of operations.

 

Critical Accounting Policies and Estimates

 

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or “GAAP.” The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reported period. In accordance with GAAP, we base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.

 

Our significant accounting policies are fully described in Note 2 to our financial statements appearing elsewhere in this Quarterly Report, and we believe those accounting policies are critical to the process of making significant judgments and estimates in the preparation of our financial statements.

 

Off-Balance Sheet Arrangements

 

None.

 

Item 3. Quantitative And Qualitative Disclosures About Market Risk.

 

As a smaller reporting company, we are not required to provide the information called for by this Item.

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures.

 

Our management is responsible for establishing and maintaining a system of “disclosure controls and procedures” (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported, within the time periods specified in the Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

11

 

 

Management’s Report on Internal Control over Financial Reporting.

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that:

 

  pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;
     
  provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and
     
  provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies or procedures may deteriorate.

 

Our management assessed the effectiveness of our internal control over financial reporting based on the parameters set forth above and has concluded that as of March 31, 2022, our internal control over financial reporting was not effective to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles as a result of the following material weaknesses:

 

  The Company does not have sufficient segregation of duties within accounting functions due to only having one officer and limited resources.
     
  The Company does not have an independent board of directors or an audit committee.
     
  The Company does not have written documentation of our internal control policies and procedures.
     
  All of the Company’s financial reporting is carried out by a financial consultant.

 

We plan to rectify these weaknesses by implementing an independent board of directors, establishing written policies and procedures for our internal control of financial reporting, and hiring additional accounting personnel at such time as we complete a reverse merger or similar business combination.

 

Changes in Internal Control over Financial Reporting.

 

There were no changes in our internal control over financial reporting during the quarter ended March 31, 2022, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

12

 

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

The Company may be involved in certain legal proceedings that arise from time to time in the ordinary course of its business. Legal expenses associated with any contingency are expensed as incurred. The Company’s officers and directors are not aware of any threatened or pending litigation to which the Company is a party or which any of its property is the subject and which would have any material, adverse effect on the Company.

 

Item 1A. Risk Factors.

 

Reference is made to the risks and uncertainties disclosed in Item 1A (“Risk Factors”) of our Annual Report on Form 10-K for the period ended December 31, 2021, filed March 31, 2022, which sections are incorporated by reference into this report, as the same may be updated from time to time. Prospective investors are encouraged to consider the risks described in our 2021 Form 10-K, and our Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in this Report and other information publicly disclosed or contained in documents we file with the Securities and Exchange Commission before purchasing our securities.

 

As a smaller reporting company, the Company is not required to disclose material changes to the Risk Factors that were contained in the 2021 Form 10-K.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

None.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

None.

 

13

 

 

Item 6. Exhibits.

 

The exhibits listed on the Exhibit Index below are provided as part of this report.

 

31.1 Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act.
   
32.1

Certification of Principal Executive Officer and Principal Financial Officer Under Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act.

 

14

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  AMERIGUARD SECURITY SERVICES, INC.
     
Dated: May 13, 2022 By: /s/ Lawrence Garcia
    Lawrence Garcia
   

Chief Executive Officer and

    Chief Financial Officer
    (Principal Executive Officer and Principal Financial Officer)

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

15

EX-31.1 2 ameriguardsecurity_ex31-1.htm EXHIBIT 31.1

 

Exhibit 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO EXCHANGE ACT RULES 13a-14(a)/15d-14(a)

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Lawrence Garcia, certify that:

 

1.

I have reviewed this Quarterly Report on Form 10-Q of Ameriguard Security Services, Inc. (formerly Health Revenue Assurance Holding, Inc.). (the “registrant”) for the quarter ended March 31, 2022;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  c)

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  d)

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an quarter report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

 

  a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: May 13, 2022 By: /s/ Lawrence Garcia
   

Lawrence Garcia

Chief Executive Officer

(Principal Executive Officer and
Principal Financial Officer)

 

 

EX-32.1 3 ameriguardsecurity_ex32-1.htm EXHIBIT 32.1

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Ameriguard Security Services, Inc. (formerly Health Revenue Assurance Holdings, Inc.) (the “Company”) on Form 10-Q for the quarter period ended March 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Lawrence Garcia, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

Dated: May 13, 2022 By: /s/ Lawrence Garcia
    Lawrence Garcia
    Chief Executive Officer
    (Principal Executive Officer and
    Principal Financial Officer)

 

 

EX-101.SCH 4 hraad-20220331.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - STATEMENT OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - STATEMENT OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - NATURE OF BUSINESS AND GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - EQUITY link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - DUE TO RELATED PARTY link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - NATURE OF BUSINESS AND GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - DUE TO RELATED PARTY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 5 hraad-20220331_cal.xml XBRL CALCULATION FILE EX-101.DEF 6 hraad-20220331_def.xml XBRL DEFINITION FILE EX-101.LAB 7 hraad-20220331_lab.xml XBRL LABEL FILE Equity Components [Axis] Series A One Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Related Party [Axis] Custodian Ventures [Member] Custodian Ventures LLC [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current Assets Cash Total Current Assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ DEFICIT LIABILITIES Current Liabilities Due to related party Total Current Liabilities STOCKHOLDERS’ DEFICIT Series A-1 Preferred Stock, par value $0.001 25,000,000 shares authorized, 10,000,000 shares issued and outstanding at March 31, 2021 and December 31, 2021, respectively Common stock, par value $0.001, 500,000,000 shares authorized, 3,417,302 (post-split) and 68,346,042 (pre-split) shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively Additional paid-in capital Accumulated deficit Total Stockholders’ Deficit TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT Preferred A-1 Stock, Shares Par Value Preferred A-1 Stock, Shares Authorized Preferred A-1 Stock, Shares Issued Preferred A-1 Stock, Shares Outstanding Common Stock, Shares Par Value Common Stock, Shares Authorized Common Stock, Shares Issued Common Stock, Shares Outstanding Income Statement [Abstract] Revenue Total Revenue Expenses General and administrative expenses Professional fees Total Operating Expenses Net Income (Loss) Net Income (Loss) Basic and diluted earnings per share Weighted average number of common shares outstanding - basic and diluted Statement [Table] Statement [Line Items] Beginning balance, value Beginning balance, Shares Reverse Split of Common Stock 1 for 20 Reverse Split of Common Stock 1 for 20, Shares Forgivness of related party debt Net loss Ending balance, value Ending balance, Shares Statement of Cash Flows [Abstract] Cash Flow from Operating Activities Net Income (Loss) Adjustments to reconcile net loss to net cash used in operating activities: Increase (Decrease) in operating assets and liabilities: Due to related party Net Cash used in operating activities Cash Flows from Financing Activities Net Cash provided by financing activities Net increase (decrease) in cash Cash at beginning of period Cash at end of period Supplemental Disclosure of Interest and Income Taxes Paid: Interest paid during the period Income taxes paid during the period Accounting Policies [Abstract] NATURE OF BUSINESS AND GOING CONCERN SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Equity [Abstract] EQUITY Related Party Transactions [Abstract] DUE TO RELATED PARTY Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Management’s Representation of Interim Financial Statements Use of Estimates Cash and cash equivalents Income taxes Net Loss per Share Recent Accounting Pronouncements Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items] Holder ownership Consideration paid Shares Accumulated deficit Cash Reverse stock split Number of post-split shares Number of pre-split shares Conversion ratio description Stock based compensation Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Related party cost Forgiveness of related party debt Notes payable-related party Commitments and contingencies Assets, Current Assets Liabilities, Current Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Net Income (Loss) Attributable to Parent Shares, Outstanding Increase (Decrease) in Due to Related Parties Net Cash Provided by (Used in) Operating Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash [Default Label] EX-101.PRE 8 hraad-20220331_pre.xml XBRL PRESENTATION FILE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover - shares
3 Months Ended
Mar. 31, 2022
May 08, 2022
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Mar. 31, 2022  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2022  
Current Fiscal Year End Date --12-31  
Entity File Number 333-173039  
Entity Registrant Name AMERIGUARD SECURITY SERVICES, INC.  
Entity Central Index Key 0001514443  
Entity Tax Identification Number 99-0363866  
Entity Incorporation, State or Country Code NV  
Entity Address, Address Line One 5470 W. Spruce Avenue  
Entity Address, Address Line Two Suite 102  
Entity Address, City or Town Fresno  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 93722  
City Area Code 559  
Local Phone Number 271-5984  
Entity Current Reporting Status No  
Entity Interactive Data Current No  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company true  
Entity Common Stock, Shares Outstanding   3,417,302
XML 10 R2.htm IDEA: XBRL DOCUMENT v3.22.1
BALANCE SHEETS (Unaudited) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Current Assets    
Cash
Total Current Assets
TOTAL ASSETS
Current Liabilities    
Due to related party 29,776 10,596
Total Current Liabilities 29,776 10,596
STOCKHOLDERS’ DEFICIT    
Series A-1 Preferred Stock, par value $0.001 25,000,000 shares authorized, 10,000,000 shares issued and outstanding at March 31, 2021 and December 31, 2021, respectively 10,000 10,000
Common stock, par value $0.001, 500,000,000 shares authorized, 3,417,302 (post-split) and 68,346,042 (pre-split) shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively 68,346 68,346
Additional paid-in capital 9,976,045 9,976,045
Accumulated deficit (10,084,167) (10,064,987)
Total Stockholders’ Deficit (29,776) (10,596)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT
XML 11 R3.htm IDEA: XBRL DOCUMENT v3.22.1
BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares
Mar. 31, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Preferred A-1 Stock, Shares Par Value $ 0.001 $ 0.001
Preferred A-1 Stock, Shares Authorized 25,000,000 25,000,000
Preferred A-1 Stock, Shares Issued 10,000,000 10,000,000
Preferred A-1 Stock, Shares Outstanding 10,000,000 10,000,000
Common Stock, Shares Par Value $ 0.001 $ 0.001
Common Stock, Shares Authorized 500,000,000 500,000,000
Common Stock, Shares Issued 3,417,302 68,346,042
Common Stock, Shares Outstanding 3,417,302 68,346,042
XML 12 R4.htm IDEA: XBRL DOCUMENT v3.22.1
STATEMENT OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Income Statement [Abstract]    
Revenue
Total Revenue
Expenses    
General and administrative expenses 2,980 5,183
Professional fees 16,200
Total Operating Expenses 19,180 5,183
Net Income (Loss) $ (19,180) $ (5,183)
Net Income (Loss)    
Basic and diluted earnings per share $ (0.01) $ (0.01)
Weighted average number of common shares outstanding - basic and diluted 3,417,302 68,346,042
XML 13 R5.htm IDEA: XBRL DOCUMENT v3.22.1
STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) - USD ($)
Series A One Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2020 $ 10,000 $ 68,346 $ 9,939,684 $ (10,043,670) $ (25,640)
Beginning balance, Shares at Dec. 31, 2020 10,000,000 68,346,042      
Net loss (5,183) (5,183)
Ending balance, value at Mar. 31, 2021 $ 10,000 $ 68,346 9,939,684 (10,048,853) (30,823)
Ending balance, Shares at Mar. 31, 2021 10,000,000 68,346,042      
Net loss (2,847) (2,847)
Ending balance, value at Jun. 30, 2021 $ 10,000 $ 68,346 9,939,684 (10,051,700) (33,670)
Ending balance, Shares at Jun. 30, 2021 10,000,000 68,346,042      
Forgivness of related party debt 36,361 36,361
Net loss (9,347) (9,347)
Ending balance, value at Sep. 30, 2021 $ 10,000 $ 68,346 36,361 (10,061,047) (6,656)
Ending balance, Shares at Sep. 30, 2021 10,000,000 68,346,042      
Net loss (3,940) (3,940)
Ending balance, value at Dec. 31, 2021 $ 10,000 $ 68,346 9,976,045 (10,064,987) (10,596)
Ending balance, Shares at Dec. 31, 2021 10,000,000 68,346,042      
Reverse Split of Common Stock 1 for 20   $ 68,346      
Reverse Split of Common Stock 1 for 20, Shares   3,417,302      
Net loss (19,180) (19,180)
Ending balance, value at Mar. 31, 2022 $ 10,000 $ 68,346 $ 9,976,045 $ (10,084,167) $ (29,776)
Ending balance, Shares at Mar. 31, 2022 10,000,000 3,417,302      
XML 14 R6.htm IDEA: XBRL DOCUMENT v3.22.1
STATEMENT OF CASH FLOWS (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Cash Flow from Operating Activities    
Net Income (Loss) $ (19,180) $ (5,183)
Increase (Decrease) in operating assets and liabilities:    
Due to related party 19,180 5,183
Net Cash used in operating activities
Cash Flows from Financing Activities    
Net Cash provided by financing activities
Net increase (decrease) in cash
Cash at beginning of period
Cash at end of period
Supplemental Disclosure of Interest and Income Taxes Paid:    
Interest paid during the period
Income taxes paid during the period
XML 15 R7.htm IDEA: XBRL DOCUMENT v3.22.1
NATURE OF BUSINESS AND GOING CONCERN
3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
NATURE OF BUSINESS AND GOING CONCERN

1 – NATURE OF BUSINESS AND GOING CONCERN

 

Overview

 

Ameriguard Security Services, Inc. (formerly Health Revenue Assurance Holdings, Inc). (the “Company”) intended to become a provider of revenue cycle services to a broad range of healthcare providers.

 

On February 10, 2012, HRAA entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Health Revenue Assurance Holdings, Inc. (formerly known as Anvex International, Inc., “HRAH”), a Nevada company, and its wholly-owned subsidiary Health Revenue Acquisition Corporation (“Acquisition Sub”), which was treated for accounting purposes as a reverse recapitalization with HRAA, considered the accounting acquirer.

 

The Company has been dormant since August 2014.

 

On July 14, 2020, as a result of a custodianship in Clark County, Nevada, Case Number: A816259, Custodian Ventures LLC (“Custodian”) was appointed Custodian of the Company.

 

On July 15, 2020, Custodian appointed David Lazar as the Company’s Chief Executive Officer, President, Secretary, Chief Financial Officer, Chief Executive Officer and Chairman of the Board of Directors.

 

On September 8, 2021, as a result of a private stock purchase agreement, 10,000,000 shares of Series A-1 Preferred Stock, $0.001 par value per share (the “Shares”) of the Company, were transferred from Custodian Ventures, LLC to Ameriguard Security Services, Inc. California corporation. As a result, the Ameriguard Security Services, Inc. California corporation, became holder of approximately 91% of the voting rights of the issued and outstanding share capital of the Company on a fully-diluted basis of the Company, and became the controlling shareholder. The consideration paid for the Shares was $450,000. In connection with the transaction, David Lazar has forgiven the Company from all debts owed to him and/or Custodian Ventures, LLC.

 

On September 8, 2021, the Company accepted the resignations from David Lazar as the Company’s Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and as a Member of the Board of Directors. Effective on the same date to fill the vacancies created by Mr. Lazar’s resignations, the Company appointed Lawrence Garcia as the Company’s President, CEO, CFO, Treasurer, Secretary, and Chairman of the Board of Directors. These resignations are in connection with the consummation of the private stock purchase agreement and was not the result of any disagreement with Company on any matter relating to Company’s operations, policies or practices.

 

On March 11, 2022, the Company, amended its articles of incorporation to change its name to Ameriguard Security Services, Inc. from Health Revenue Assurance Holdings, Inc. The name was deemed effective by FINRA on March 17, 2022.

 

Going Concern

 

The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the twelve months following the date of these financial statements. As of March 31, 2022, the Company had no cash and an accumulated deficit of $10,084,167.

 

Because the Company does not expect that existing operational cash flow will be sufficient to fund presently anticipated operations, this raises substantial doubt about the Company’s ability to continue as a going concern. Therefore, the Company will need to raise additional funds and is currently exploring alternative sources of financing. Recently the Company is being funded by Ameriguard Security Services, Inc., California corporation which has extended interest-free demand loans to the Company. Historically, the Company raised capital through private placements, to finance working capital needs and may attempt to raise capital through the sale of common stock or other securities and obtaining some short-term loans. The Company will be required to continue to so until its operations become profitable. Also, the Company has, in the past, paid for consulting services with its common stock to maximize working capital, and intends to continue this practice where feasible.

 

XML 16 R8.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying financial statements have been prepared in accordance with the Financial Accounting Standards Board (“FASB”) “FASB Accounting Standard Codification™” (the “Codification”) which is the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) in the United States.

 

Management’s Representation of Interim Financial Statements

 

The accompanying unaudited financial statements have been prepared by the Company without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The Company uses the same accounting policies in preparing quarterly and annual financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted as allowed by such rules and regulations, and management believes that the disclosures are adequate to make the information presented not misleading. These financial statements include all the adjustments, which in the opinion of management are necessary to a fair presentation of financial position and results of operations. All such adjustments are of a normal and recurring nature. Interim results are not necessarily indicative of results for a full year. These financial statements should be read in conjunction with the audited financial statements and notes thereto on December 31, 2021, as presented in the Company’s Annual Report on Form 10-K.

 

Use of Estimates

 

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to income taxes and contingencies. The Company bases its estimates on historical experience, known or expected trends, and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.

 

Cash and cash equivalents

 

The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. The Company had no cash on hand as of March 31, 2022, and December 31, 2021, respectively.

 

Income taxes

 

The Company accounts for income taxes under FASB ASC 740, “Accounting for Income Taxes”. Under FASB ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under FASB ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. FASB ASC 740-10-05, “Accounting for Uncertainty in Income Taxes” prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities.

 

The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. The Company assesses the validity of its conclusions regarding uncertain tax positions quarterly to determine if facts or circumstances have arisen that might cause it to change its judgment regarding the likelihood of a tax position’s sustainability under audit.

 

Net Loss per Share

 

Net loss per common share is computed by dividing net loss by the weighted average common shares outstanding during the period as defined by Financial Accounting Standards, ASC Topic 260, “Earnings per Share.” Basic earnings per common share (“EPS”) calculations are determined by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding.

 

Recent Accounting Pronouncements

 

There are no recent accounting pronouncements that impact the Company’s operations.

 

XML 17 R9.htm IDEA: XBRL DOCUMENT v3.22.1
EQUITY
3 Months Ended
Mar. 31, 2022
Equity [Abstract]  
EQUITY

3 – EQUITY

 

Common Stock

 

On March 11, 2022, the Company amended its articles of incorporation to reverse split its Common Stock at a rate of one-for-20, which was declared effective by FINRA on March 17, 2022. The Common Stock was reverse split to post-split 3,417,302 shares from pre-split 68,346,042 common shares.

 

The Company has authorized 500,000,000 shares of $0.001 par value, Common Stock. As of March 31, 2022 and December 31, 2021, there were 3,417,302 (pre-split 68,346,042) and 68,346,042 (post-split 3,417,302) shares of Common Stock issued and outstanding, respectively.

 

Preferred Stock

 

On November 16, 2020, the Company designated, out of the Twenty-five Million (25,000,000) shares of preferred stock, par value $0.001 per share, of Series A-1 Preferred Stock, consisting of Ten Million (10,000,000) shares, which are convertible to common stock at the conversion ratio of 72 shares of common stock for each share of preferred stock. These shares were awarded to Custodian Ventures, managed by former officer and director David Lazar, for services performed for the Company. These shares were valued at par value assuming all of the preferred shares were converted to common stock, or $720,000 which was recorded as stock-based compensation.

 

On September 8, 2021, in a private transaction Custodian Ventures LLC sold its Series A-1 Preferred Stock to Ameriguard Security Services, Inc., California corporation. The officer and control person of Ameriguard Security Services, Inc., California corporation is Lawrence Garcia, the Company’s President, CEO, CFO, Treasurer, Secretary, and Chairman of the Board of Directors.

 

As of March 31, 2022 and December 31, 2021, there were 10,000,000 shares of Series A-1 Preferred Stock issued and outstanding, respectively.

 

XML 18 R10.htm IDEA: XBRL DOCUMENT v3.22.1
DUE TO RELATED PARTY
3 Months Ended
Mar. 31, 2022
Related Party Transactions [Abstract]  
DUE TO RELATED PARTY

4 – DUE TO RELATED PARTY

 

As of September 8, 2021, the Company had a due to related party Custodian Ventures LLC, of which former officer and director David Lazar is a managing member, totaling $36,361. On September 8, 2021, the $36,361 was forgiven in full by Custodian Ventures LLC and the Company recorded the resulting gain as additional paid-in capital.

 

During the quarter ended March 31, 2022, Ameriguard Security Services, Inc., California corporation paid expenses on behalf of the Company totaling $19,180. As of March 31, 2022, the Company had a balance due to related party totaling $29,776.

 

XML 19 R11.htm IDEA: XBRL DOCUMENT v3.22.1
COMMITMENTS AND CONTINGENCIES
3 Months Ended
Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

5 – COMMITMENTS AND CONTINGENCIES

 

The Company did not have any contractual commitments as of March 31,2022, and December 31, 2021, respectively.

 

XML 20 R12.htm IDEA: XBRL DOCUMENT v3.22.1
SUBSEQUENT EVENTS
3 Months Ended
Mar. 31, 2022
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

6 – SUBSEQUENT EVENTS

 

In accordance with SFAS 165 (ASC 855-10) management has performed an evaluation of subsequent events through the date that the financial statements were available to be issued and has determined that it does not have any material subsequent events to disclose in these financial statements.

XML 21 R13.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
3 Months Ended
Mar. 31, 2022
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying financial statements have been prepared in accordance with the Financial Accounting Standards Board (“FASB”) “FASB Accounting Standard Codification™” (the “Codification”) which is the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) in the United States.

 

Management’s Representation of Interim Financial Statements

Management’s Representation of Interim Financial Statements

 

The accompanying unaudited financial statements have been prepared by the Company without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The Company uses the same accounting policies in preparing quarterly and annual financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted as allowed by such rules and regulations, and management believes that the disclosures are adequate to make the information presented not misleading. These financial statements include all the adjustments, which in the opinion of management are necessary to a fair presentation of financial position and results of operations. All such adjustments are of a normal and recurring nature. Interim results are not necessarily indicative of results for a full year. These financial statements should be read in conjunction with the audited financial statements and notes thereto on December 31, 2021, as presented in the Company’s Annual Report on Form 10-K.

 

Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to income taxes and contingencies. The Company bases its estimates on historical experience, known or expected trends, and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.

 

Cash and cash equivalents

Cash and cash equivalents

 

The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. The Company had no cash on hand as of March 31, 2022, and December 31, 2021, respectively.

 

Income taxes

Income taxes

 

The Company accounts for income taxes under FASB ASC 740, “Accounting for Income Taxes”. Under FASB ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under FASB ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. FASB ASC 740-10-05, “Accounting for Uncertainty in Income Taxes” prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities.

 

The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. The Company assesses the validity of its conclusions regarding uncertain tax positions quarterly to determine if facts or circumstances have arisen that might cause it to change its judgment regarding the likelihood of a tax position’s sustainability under audit.

 

Net Loss per Share

Net Loss per Share

 

Net loss per common share is computed by dividing net loss by the weighted average common shares outstanding during the period as defined by Financial Accounting Standards, ASC Topic 260, “Earnings per Share.” Basic earnings per common share (“EPS”) calculations are determined by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding.

 

Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

There are no recent accounting pronouncements that impact the Company’s operations.

 

XML 22 R14.htm IDEA: XBRL DOCUMENT v3.22.1
NATURE OF BUSINESS AND GOING CONCERN (Details Narrative) - USD ($)
Sep. 08, 2021
Mar. 31, 2022
Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]      
Preferred A-1 Stock, Shares Authorized   25,000,000 25,000,000
Preferred A-1 Stock, Shares Par Value   $ 0.001 $ 0.001
Holder ownership 91.00%    
Consideration paid Shares $ 450,000    
Accumulated deficit   $ 10,084,167 $ 10,064,987
Custodian Ventures [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Preferred A-1 Stock, Shares Authorized 10,000,000    
Preferred A-1 Stock, Shares Par Value $ 0.001    
XML 23 R15.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Accounting Policies [Abstract]    
Cash $ 0 $ 0
XML 24 R16.htm IDEA: XBRL DOCUMENT v3.22.1
EQUITY (Details Narrative) - USD ($)
3 Months Ended
Mar. 11, 2022
Mar. 31, 2022
Dec. 31, 2021
Equity [Abstract]      
Reverse stock split one-for-20    
Number of post-split shares 3,417,302    
Number of pre-split shares 68,346,042    
Common Stock, Shares Authorized   500,000,000 500,000,000
Common Stock, Shares Par Value   $ 0.001 $ 0.001
Common Stock, Shares Issued   3,417,302 68,346,042
Common Stock, Shares Outstanding   3,417,302 68,346,042
Preferred A-1 Stock, Shares Authorized   25,000,000 25,000,000
Preferred A-1 Stock, Shares Par Value   $ 0.001 $ 0.001
Conversion ratio description   the conversion ratio of 72 shares of common stock for each share of preferred stock.  
Stock based compensation   $ 720,000  
Preferred A-1 Stock, Shares Issued   10,000,000 10,000,000
Preferred A-1 Stock, Shares Outstanding   10,000,000 10,000,000
XML 25 R17.htm IDEA: XBRL DOCUMENT v3.22.1
DUE TO RELATED PARTY (Details Narrative) - USD ($)
3 Months Ended
Sep. 08, 2021
Mar. 31, 2022
Related Party Transaction [Line Items]    
Related party cost   $ 19,180
Notes payable-related party   $ 29,776
Custodian Ventures LLC [Member]    
Related Party Transaction [Line Items]    
Related party cost $ 36,361  
Forgiveness of related party debt $ 36,361  
XML 26 R18.htm IDEA: XBRL DOCUMENT v3.22.1
COMMITMENTS AND CONTINGENCIES (Details Narrative)
Mar. 31, 2022
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
Commitments and contingencies $ 0
XML 27 ameriguardsecurity_10q_htm.xml IDEA: XBRL DOCUMENT 0001514443 2022-01-01 2022-03-31 0001514443 2022-05-08 0001514443 2022-03-31 0001514443 2021-12-31 0001514443 2021-01-01 2021-03-31 0001514443 hraad:SeriesAOnePreferredStockMember 2020-12-31 0001514443 us-gaap:CommonStockMember 2020-12-31 0001514443 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001514443 us-gaap:RetainedEarningsMember 2020-12-31 0001514443 2020-12-31 0001514443 hraad:SeriesAOnePreferredStockMember 2021-03-31 0001514443 us-gaap:CommonStockMember 2021-03-31 0001514443 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001514443 us-gaap:RetainedEarningsMember 2021-03-31 0001514443 2021-03-31 0001514443 hraad:SeriesAOnePreferredStockMember 2021-06-30 0001514443 us-gaap:CommonStockMember 2021-06-30 0001514443 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001514443 us-gaap:RetainedEarningsMember 2021-06-30 0001514443 2021-06-30 0001514443 hraad:SeriesAOnePreferredStockMember 2021-09-30 0001514443 us-gaap:CommonStockMember 2021-09-30 0001514443 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001514443 us-gaap:RetainedEarningsMember 2021-09-30 0001514443 2021-09-30 0001514443 hraad:SeriesAOnePreferredStockMember 2021-12-31 0001514443 us-gaap:CommonStockMember 2021-12-31 0001514443 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001514443 us-gaap:RetainedEarningsMember 2021-12-31 0001514443 hraad:SeriesAOnePreferredStockMember 2021-01-01 2021-03-31 0001514443 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001514443 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001514443 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001514443 hraad:SeriesAOnePreferredStockMember 2021-04-01 2021-06-30 0001514443 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001514443 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001514443 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001514443 2021-04-01 2021-06-30 0001514443 hraad:SeriesAOnePreferredStockMember 2021-07-01 2021-09-30 0001514443 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001514443 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001514443 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001514443 2021-07-01 2021-09-30 0001514443 hraad:SeriesAOnePreferredStockMember 2021-10-01 2021-12-31 0001514443 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0001514443 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0001514443 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0001514443 2021-10-01 2021-12-31 0001514443 hraad:SeriesAOnePreferredStockMember 2022-01-01 2022-03-31 0001514443 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001514443 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001514443 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001514443 hraad:SeriesAOnePreferredStockMember 2022-03-31 0001514443 us-gaap:CommonStockMember 2022-03-31 0001514443 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001514443 us-gaap:RetainedEarningsMember 2022-03-31 0001514443 hraad:CustodianVenturesMember 2021-09-08 0001514443 2021-09-08 0001514443 2021-09-01 2021-09-08 0001514443 2022-03-01 2022-03-11 0001514443 2022-03-11 0001514443 hraad:CustodianVenturesLLCMember 2021-09-01 2021-09-08 iso4217:USD shares iso4217:USD shares pure 0001514443 false --12-31 2022 Q1 10-Q true 2022-03-31 false 333-173039 AMERIGUARD SECURITY SERVICES, INC. NV 99-0363866 5470 W. Spruce Avenue Suite 102 Fresno CA 93722 559 271-5984 No No Non-accelerated Filer true false true 3417302 29776 10596 29776 10596 0.001 0.001 25000000 25000000 10000000 10000000 10000000 10000000 10000 10000 0.001 0.001 500000000 500000000 3417302 3417302 68346042 68346042 68346 68346 9976045 9976045 -10084167 -10064987 -29776 -10596 2980 5183 16200 19180 5183 -19180 -5183 -0.01 -0.01 3417302 68346042 10000000 10000 68346042 68346 9939684 -10043670 -25640 -5183 -5183 10000000 10000 68346042 68346 9939684 -10048853 -30823 -2847 -2847 10000000 10000 68346042 68346 9939684 -10051700 -33670 36361 36361 -9347 -9347 10000000 10000 68346042 68346 36361 -10061047 -6656 -3940 -3940 10000000 10000 68346042 68346 9976045 -10064987 -10596 3417302 68346 -19180 -19180 10000000 10000 3417302 68346 9976045 -10084167 -29776 -19180 -5183 19180 5183 <p id="xdx_804_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zfTaBQPUWNfi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1 – <span id="xdx_822_zInFky5R3WK9">NATURE OF BUSINESS AND GOING CONCERN</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ameriguard Security Services, Inc. (formerly Health Revenue Assurance Holdings, Inc). (the “Company”) intended to become a provider of revenue cycle services to a broad range of healthcare providers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 10, 2012, HRAA entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Health Revenue Assurance Holdings, Inc. (formerly known as Anvex International, Inc., “HRAH”), a Nevada company, and its wholly-owned subsidiary Health Revenue Acquisition Corporation (“Acquisition Sub”), which was treated for accounting purposes as a reverse recapitalization with HRAA, considered the accounting acquirer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has been dormant since August 2014.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 14, 2020, as a result of a custodianship in Clark County, Nevada, Case Number: A816259, Custodian Ventures LLC (“Custodian”) was appointed Custodian of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 15, 2020, Custodian appointed David Lazar as the Company’s Chief Executive Officer, President, Secretary, Chief Financial Officer, Chief Executive Officer and Chairman of the Board of Directors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 8, 2021, as a result of a private stock purchase agreement, <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_c20210908__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CustodianVenturesMember_pdd" title="Preferred A-1 Stock, Shares Authorized">10,000,000</span> shares of Series A-1 Preferred Stock, $<span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_c20210908__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CustodianVenturesMember_pdd" title="Preferred A-1 Stock, Shares Par Value">0.001</span> par value per share (the “Shares”) of the Company, were transferred from Custodian Ventures, LLC to Ameriguard Security Services, Inc. California corporation. As a result, the Ameriguard Security Services, Inc. California corporation, became holder of approximately <span id="xdx_901_ecustom--HolderOwnership_iI_dp_c20210908_z4tKnEM7lysb" title="Holder ownership">91</span>% of the voting rights of the issued and outstanding share capital of the Company on a fully-diluted basis of the Company, and became the controlling shareholder. The consideration paid for the Shares was $<span id="xdx_909_ecustom--ConsiderationPaidShares_c20210901__20210908_pp0p0" title="Consideration paid Shares">450,000</span>. In connection with the transaction, David Lazar has forgiven the Company from all debts owed to him and/or Custodian Ventures, LLC.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 8, 2021, the Company accepted the resignations from David Lazar as the Company’s Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and as a Member of the Board of Directors. Effective on the same date to fill the vacancies created by Mr. Lazar’s resignations, the Company appointed Lawrence Garcia as the Company’s President, CEO, CFO, Treasurer, Secretary, and Chairman of the Board of Directors. These resignations are in connection with the consummation of the private stock purchase agreement and was not the result of any disagreement with Company on any matter relating to Company’s operations, policies or practices.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 11, 2022, the Company, amended its articles of incorporation to change its name to Ameriguard Security Services, Inc. from Health Revenue Assurance Holdings, Inc. The name was deemed effective by FINRA on March 17, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going Concern</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the twelve months following the date of these financial statements. As of March 31, 2022, the Company had no cash and an accumulated deficit of $<span id="xdx_906_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20220331_z9H1b3QXrl86" title="Accumulated deficit">10,084,167</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because the Company does not expect that existing operational cash flow will be sufficient to fund presently anticipated operations, this raises substantial doubt about the Company’s ability to continue as a going concern. Therefore, the Company will need to raise additional funds and is currently exploring alternative sources of financing. Recently the Company is being funded by Ameriguard Security Services, Inc., California corporation which has extended interest-free demand loans to the Company. Historically, the Company raised capital through private placements, to finance working capital needs and may attempt to raise capital through the sale of common stock or other securities and obtaining some short-term loans. The Company will be required to continue to so until its operations become profitable. Also, the Company has, in the past, paid for consulting services with its common stock to maximize working capital, and intends to continue this practice where feasible.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 10000000 0.001 0.91 450000 -10084167 <p id="xdx_80C_eus-gaap--SignificantAccountingPoliciesTextBlock_zN1DXl99FDV3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2 – <span id="xdx_820_zDyOKACpD79h">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_znl5fojNJ8za" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_ziaOn4lV6bf5">Basis of Presentation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared in accordance with the Financial Accounting Standards Board (“FASB”) “FASB Accounting Standard Codification™” (the “Codification”) which is the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) in the United States.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_ecustom--ManagementsRepresentationOfInterimFinancialStatementsPolicyTextBlock_zxKIHZ1QNeqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zv5grZMCRZRl">Management’s Representation of Interim Financial Statements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited financial statements have been prepared by the Company without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The Company uses the same accounting policies in preparing quarterly and annual financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted as allowed by such rules and regulations, and management believes that the disclosures are adequate to make the information presented not misleading. These financial statements include all the adjustments, which in the opinion of management are necessary to a fair presentation of financial position and results of operations. All such adjustments are of a normal and recurring nature. Interim results are not necessarily indicative of results for a full year. These financial statements should be read in conjunction with the audited financial statements and notes thereto on December 31, 2021, as presented in the Company’s Annual Report on Form 10-K.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--UseOfEstimates_zC6d2j2GHiDg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zJ4ygN3s6R9">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to income taxes and contingencies. The Company bases its estimates on historical experience, known or expected trends, and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zvyk7dN7tjhf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_z8hPq4ODsxql">Cash and cash equivalents</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. The Company had <span id="xdx_906_eus-gaap--Cash_iI_pp0p0_do_c20220331_z2bTz9mP5YOf" title="Cash"><span id="xdx_90B_eus-gaap--Cash_iI_pp0p0_do_c20211231_zBBQYvbaep5k" title="Cash">no</span></span> cash on hand as of March 31, 2022, and December 31, 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zH1e8urXanKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zDThCN2YEIJf">Income taxes</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes under FASB ASC 740, “Accounting for Income Taxes”. Under FASB ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under FASB ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. FASB ASC 740-10-05, “Accounting for Uncertainty in Income Taxes” prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. The Company assesses the validity of its conclusions regarding uncertain tax positions quarterly to determine if facts or circumstances have arisen that might cause it to change its judgment regarding the likelihood of a tax position’s sustainability under audit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zJh30OpLYo0c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zopqPw9uEi21">Net Loss per Share</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss per common share is computed by dividing net loss by the weighted average common shares outstanding during the period as defined by Financial Accounting Standards, ASC Topic 260, “Earnings per Share.” Basic earnings per common share (“EPS”) calculations are determined by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z06RGULMUDBl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zRnGFccG01a3">Recent Accounting Pronouncements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There are no recent accounting pronouncements that impact the Company’s operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_znl5fojNJ8za" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_ziaOn4lV6bf5">Basis of Presentation</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared in accordance with the Financial Accounting Standards Board (“FASB”) “FASB Accounting Standard Codification™” (the “Codification”) which is the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) in the United States.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_ecustom--ManagementsRepresentationOfInterimFinancialStatementsPolicyTextBlock_zxKIHZ1QNeqa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_862_zv5grZMCRZRl">Management’s Representation of Interim Financial Statements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited financial statements have been prepared by the Company without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). The Company uses the same accounting policies in preparing quarterly and annual financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) have been condensed or omitted as allowed by such rules and regulations, and management believes that the disclosures are adequate to make the information presented not misleading. These financial statements include all the adjustments, which in the opinion of management are necessary to a fair presentation of financial position and results of operations. All such adjustments are of a normal and recurring nature. Interim results are not necessarily indicative of results for a full year. These financial statements should be read in conjunction with the audited financial statements and notes thereto on December 31, 2021, as presented in the Company’s Annual Report on Form 10-K.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--UseOfEstimates_zC6d2j2GHiDg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zJ4ygN3s6R9">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to income taxes and contingencies. The Company bases its estimates on historical experience, known or expected trends, and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zvyk7dN7tjhf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_z8hPq4ODsxql">Cash and cash equivalents</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. The Company had <span id="xdx_906_eus-gaap--Cash_iI_pp0p0_do_c20220331_z2bTz9mP5YOf" title="Cash"><span id="xdx_90B_eus-gaap--Cash_iI_pp0p0_do_c20211231_zBBQYvbaep5k" title="Cash">no</span></span> cash on hand as of March 31, 2022, and December 31, 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 0 <p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zH1e8urXanKk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zDThCN2YEIJf">Income taxes</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes under FASB ASC 740, “Accounting for Income Taxes”. Under FASB ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under FASB ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. FASB ASC 740-10-05, “Accounting for Uncertainty in Income Taxes” prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. The Company assesses the validity of its conclusions regarding uncertain tax positions quarterly to determine if facts or circumstances have arisen that might cause it to change its judgment regarding the likelihood of a tax position’s sustainability under audit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zJh30OpLYo0c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zopqPw9uEi21">Net Loss per Share</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss per common share is computed by dividing net loss by the weighted average common shares outstanding during the period as defined by Financial Accounting Standards, ASC Topic 260, “Earnings per Share.” Basic earnings per common share (“EPS”) calculations are determined by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z06RGULMUDBl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zRnGFccG01a3">Recent Accounting Pronouncements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There are no recent accounting pronouncements that impact the Company’s operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_80B_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zmBAVMXDlpAh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3 – <span id="xdx_821_zuar1vNFSPAg">EQUITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common Stock</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 11, 2022, the Company amended its articles of incorporation to reverse split its Common Stock at a rate of <span id="xdx_905_eus-gaap--StockholdersEquityReverseStockSplit_c20220301__20220311_zz6dWIZN7Hk6" title="Reverse stock split">one-for-20</span>, which was declared effective by FINRA on March 17, 2022. The Common Stock was reverse split to post-split <span id="xdx_906_ecustom--NumberOfPostsplitShares_iI_c20220311_zhNiq7u1sQP8" title="Number of post-split shares">3,417,302</span> shares from pre-split <span id="xdx_907_ecustom--NumberOfPresplitShares_iI_c20220311_zl9mjqJa2Glg" title="Number of pre-split shares">68,346,042</span> common shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has authorized <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_c20220331_z5tGCeaNTdm1" title="Common Stock, Shares Authorized"><span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_zKtDIvGwWqib" title="Common Stock, Shares Authorized">500,000,000</span></span> shares of $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220331_ztUcLLkshyq3" title="Common Stock, Shares Par Value"><span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20211231_zEEWJ0kvejR6" title="Common Stock, Shares Par Value">0.001</span></span> par value, Common Stock. As of March 31, 2022 and December 31, 2021, there were <span id="xdx_902_eus-gaap--CommonStockSharesIssued_iI_c20220331_z8Sx6wc826a3" title="Common Stock, Shares Issued"><span id="xdx_908_eus-gaap--CommonStockSharesOutstanding_iI_c20220331_zgoEPCKV3ejh" title="Common Stock, Shares Outstanding">3,417,302</span></span> (pre-split 68,346,042) and <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_c20211231_zKbmJRCCl8Ej" title="Common Stock, Shares Issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_z7ZSl5ktKWH2" title="Common Stock, Shares Outstanding">68,346,042</span></span> (post-split 3,417,302) shares of Common Stock issued and outstanding, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred Stock</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 16, 2020, the Company designated, out of the Twenty-five Million (<span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20220331_zfdgwc71pxrl" title="Preferred A-1 Stock, Shares Authorized"><span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231_zaUDyFt0fQll" title="Preferred A-1 Stock, Shares Authorized">25,000,000</span></span>) shares of preferred stock, par value $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20220331_zJvWz8yMlg1c" title="Preferred A-1 Stock, Shares Par Value"><span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20211231_zij9YCJK6q1b" title="Preferred A-1 Stock, Shares Par Value">0.001</span></span> per share, of Series A-1 Preferred Stock, consisting of Ten Million (10,000,000) shares, which are convertible to common stock at <span id="xdx_90C_eus-gaap--CommonStockConversionBasis_c20220101__20220331" title="Conversion ratio description">the conversion ratio of 72 shares of common stock for each share of preferred stock.</span> These shares were awarded to Custodian Ventures, managed by former officer and director David Lazar, for services performed for the Company. These shares were valued at par value assuming all of the preferred shares were converted to common stock, or $<span id="xdx_904_eus-gaap--ShareBasedCompensation_c20220101__20220331_pp0p0" title="Stock based compensation">720,000</span> which was recorded as stock-based compensation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 8, 2021, in a private transaction Custodian Ventures LLC sold its Series A-1 Preferred Stock to Ameriguard Security Services, Inc., California corporation. The officer and control person of Ameriguard Security Services, Inc., California corporation is Lawrence Garcia, the Company’s President, CEO, CFO, Treasurer, Secretary, and Chairman of the Board of Directors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2022 and December 31, 2021, there were <span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_c20220331_zUaCRc4RoxSf" title="Preferred A-1 Stock, Shares Issued"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_c20220331_zpoj54ak3U1" title="Preferred A-1 Stock, Shares Outstanding"><span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_c20211231_z2QNbgnr5BZf" title="Preferred A-1 Stock, Shares Issued"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_c20211231_zgf6sK7Aket3" title="Preferred A-1 Stock, Shares Outstanding">10,000,000</span></span></span></span> shares of Series A-1 Preferred Stock issued and outstanding, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> one-for-20 3417302 68346042 500000000 500000000 0.001 0.001 3417302 3417302 68346042 68346042 25000000 25000000 0.001 0.001 the conversion ratio of 72 shares of common stock for each share of preferred stock. 720000 10000000 10000000 10000000 10000000 <p id="xdx_80D_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zPtmcDyKWvI2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4 – <span id="xdx_828_zlTDYroEpkW1">DUE TO RELATED PARTY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 8, 2021, the Company had a due to related party Custodian Ventures LLC, of which former officer and director David Lazar is a managing member, totaling $<span id="xdx_908_eus-gaap--RelatedPartyCosts_c20210901__20210908__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CustodianVenturesLLCMember_pp0p0" title="Related party cost">36,361</span>. On September 8, 2021, the $<span id="xdx_90F_ecustom--ForgivenessOfRelatedPartyDebt_c20210901__20210908__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CustodianVenturesLLCMember_pp0p0" title="Forgiveness of related party debt">36,361</span> was forgiven in full by Custodian Ventures LLC and the Company recorded the resulting gain as additional paid-in capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the quarter ended March 31, 2022, Ameriguard Security Services, Inc., California corporation paid expenses on behalf of the Company totaling $<span id="xdx_90B_eus-gaap--RelatedPartyCosts_c20220101__20220331_pp0p0" title="Related party cost">19,180</span>. As of March 31, 2022, the Company had a balance due to related party totaling $<span id="xdx_90B_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_c20220331_pp0p0" title="Notes payable-related party">29,776</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 36361 36361 19180 29776 <p id="xdx_80C_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zOdM63HTF4Ai" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5 – <span id="xdx_827_zXOitVYdysM3">COMMITMENTS AND CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company did <span id="xdx_900_eus-gaap--CommitmentsAndContingencies_iI_do_c20220331_zF5i5mzh2atf" title="Commitments and contingencies">no</span>t have any contractual commitments as of March 31,2022, and December 31, 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 <p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_zCqKACHLIeb8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6 – <span id="xdx_825_zejnL06zNJV7">SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with SFAS 165 (ASC 855-10) management has performed an evaluation of subsequent events through the date that the financial statements were available to be issued and has determined that it does not have any material subsequent events to disclose in these financial statements.</span></p> EXCEL 28 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

8K52[6SX'G@( .L, M / " ?Y; !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 M" 7F*U4/P[=3!4! "M"P &@ @ ')7@ >&PO7W)E;',O M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " 7F*U404"D9EL! #@# M$P @ $68 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 ..&@ : .T& "B80 ! end XML 29 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 30 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 31 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 62 90 1 false 6 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://healthrevenue.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - BALANCE SHEETS (Unaudited) Sheet http://healthrevenue.com/role/BalanceSheets BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://healthrevenue.com/role/BalanceSheetsParenthetical BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - STATEMENT OF OPERATIONS (Unaudited) Sheet http://healthrevenue.com/role/StatementOfOperations STATEMENT OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) Sheet http://healthrevenue.com/role/StatementsOfStockholdersEquityDeficit STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - STATEMENT OF CASH FLOWS (Unaudited) Sheet http://healthrevenue.com/role/StatementOfCashFlows STATEMENT OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - NATURE OF BUSINESS AND GOING CONCERN Sheet http://healthrevenue.com/role/NatureOfBusinessAndGoingConcern NATURE OF BUSINESS AND GOING CONCERN Notes 7 false false R8.htm 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://healthrevenue.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - EQUITY Sheet http://healthrevenue.com/role/Equity EQUITY Notes 9 false false R10.htm 00000010 - Disclosure - DUE TO RELATED PARTY Sheet http://healthrevenue.com/role/DueToRelatedParty DUE TO RELATED PARTY Notes 10 false false R11.htm 00000011 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://healthrevenue.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 11 false false R12.htm 00000012 - Disclosure - SUBSEQUENT EVENTS Sheet http://healthrevenue.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 12 false false R13.htm 00000013 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 13 false false R14.htm 00000014 - Disclosure - NATURE OF BUSINESS AND GOING CONCERN (Details Narrative) Sheet http://healthrevenue.com/role/NatureOfBusinessAndGoingConcernDetailsNarrative NATURE OF BUSINESS AND GOING CONCERN (Details Narrative) Details http://healthrevenue.com/role/NatureOfBusinessAndGoingConcern 14 false false R15.htm 00000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesPolicies 15 false false R16.htm 00000016 - Disclosure - EQUITY (Details Narrative) Sheet http://healthrevenue.com/role/EquityDetailsNarrative EQUITY (Details Narrative) Details http://healthrevenue.com/role/Equity 16 false false R17.htm 00000017 - Disclosure - DUE TO RELATED PARTY (Details Narrative) Sheet http://healthrevenue.com/role/DueToRelatedPartyDetailsNarrative DUE TO RELATED PARTY (Details Narrative) Details http://healthrevenue.com/role/DueToRelatedParty 17 false false R18.htm 00000018 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://healthrevenue.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://healthrevenue.com/role/CommitmentsAndContingencies 18 false false All Reports Book All Reports ameriguardsecurity_10q.htm ameriguardsecurity_ex31-1.htm ameriguardsecurity_ex32-1.htm hraad-20220331.xsd hraad-20220331_cal.xml hraad-20220331_def.xml hraad-20220331_lab.xml hraad-20220331_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 33 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ameriguardsecurity_10q.htm": { "axisCustom": 0, "axisStandard": 2, "contextCount": 62, "dts": { "calculationLink": { "local": [ "hraad-20220331_cal.xml" ] }, "definitionLink": { "local": [ "hraad-20220331_def.xml" ] }, "inline": { "local": [ "ameriguardsecurity_10q.htm" ] }, "labelLink": { "local": [ "hraad-20220331_lab.xml" ] }, "presentationLink": { "local": [ "hraad-20220331_pre.xml" ] }, "schema": { "local": [ "hraad-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 160, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 40, "http://healthrevenue.com/20220331": 5, "http://xbrl.sec.gov/dei/2022": 5, "total": 50 }, "keyCustom": 12, "keyStandard": 78, "memberCustom": 3, "memberStandard": 3, "nsprefix": "hraad", "nsuri": "http://healthrevenue.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://healthrevenue.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - DUE TO RELATED PARTY", "role": "http://healthrevenue.com/role/DueToRelatedParty", "shortName": "DUE TO RELATED PARTY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://healthrevenue.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - SUBSEQUENT EVENTS", "role": "http://healthrevenue.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - NATURE OF BUSINESS AND GOING CONCERN (Details Narrative)", "role": "http://healthrevenue.com/role/NatureOfBusinessAndGoingConcernDetailsNarrative", "shortName": "NATURE OF BUSINESS AND GOING CONCERN (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "AsOf2021-09-08", "decimals": "INF", "lang": null, "name": "hraad:HolderOwnership", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "role": "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "From2022-03-012022-03-11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - EQUITY (Details Narrative)", "role": "http://healthrevenue.com/role/EquityDetailsNarrative", "shortName": "EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "From2022-03-012022-03-11", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RelatedPartyCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - DUE TO RELATED PARTY (Details Narrative)", "role": "http://healthrevenue.com/role/DueToRelatedPartyDetailsNarrative", "shortName": "DUE TO RELATED PARTY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RelatedPartyCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommitmentsAndContingencies", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "role": "http://healthrevenue.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommitmentsAndContingencies", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - BALANCE SHEETS (Unaudited)", "role": "http://healthrevenue.com/role/BalanceSheets", "shortName": "BALANCE SHEETS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - BALANCE SHEETS (Unaudited) (Parenthetical)", "role": "http://healthrevenue.com/role/BalanceSheetsParenthetical", "shortName": "BALANCE SHEETS (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - STATEMENT OF OPERATIONS (Unaudited)", "role": "http://healthrevenue.com/role/StatementOfOperations", "shortName": "STATEMENT OF OPERATIONS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "AsOf2020-12-31_custom_SeriesAOnePreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)", "role": "http://healthrevenue.com/role/StatementsOfStockholdersEquityDeficit", "shortName": "STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "AsOf2020-12-31_custom_SeriesAOnePreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - STATEMENT OF CASH FLOWS (Unaudited)", "role": "http://healthrevenue.com/role/StatementOfCashFlows", "shortName": "STATEMENT OF CASH FLOWS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "lang": null, "name": "us-gaap:IncreaseDecreaseInDueToRelatedParties", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - NATURE OF BUSINESS AND GOING CONCERN", "role": "http://healthrevenue.com/role/NatureOfBusinessAndGoingConcern", "shortName": "NATURE OF BUSINESS AND GOING CONCERN", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://healthrevenue.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - EQUITY", "role": "http://healthrevenue.com/role/Equity", "shortName": "EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsecurity_10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 6, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r216", "r218", "r219" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r211" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r221" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r222" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r213" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r206" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r209" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r215" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "hraad_BasicAndDilutedEarningsPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Basic and diluted earnings per share" } } }, "localname": "BasicAndDilutedEarningsPerShare", "nsuri": "http://healthrevenue.com/20220331", "presentation": [ "http://healthrevenue.com/role/StatementOfOperations" ], "xbrltype": "perShareItemType" }, "hraad_ConsiderationPaidShares": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Consideration paid Shares" } } }, "localname": "ConsiderationPaidShares", "nsuri": "http://healthrevenue.com/20220331", "presentation": [ "http://healthrevenue.com/role/NatureOfBusinessAndGoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "hraad_CustodianVenturesLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Custodian Ventures LLC [Member]" } } }, "localname": "CustodianVenturesLLCMember", "nsuri": "http://healthrevenue.com/20220331", "presentation": [ "http://healthrevenue.com/role/DueToRelatedPartyDetailsNarrative" ], "xbrltype": "domainItemType" }, "hraad_CustodianVenturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Custodian Ventures [Member]" } } }, "localname": "CustodianVenturesMember", "nsuri": "http://healthrevenue.com/20220331", "presentation": [ "http://healthrevenue.com/role/NatureOfBusinessAndGoingConcernDetailsNarrative" ], "xbrltype": "domainItemType" }, "hraad_ForgivenessOfRelatedPartyDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Forgiveness of related party debt" } } }, "localname": "ForgivenessOfRelatedPartyDebt", "nsuri": "http://healthrevenue.com/20220331", "presentation": [ "http://healthrevenue.com/role/DueToRelatedPartyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "hraad_ForgivenessOfRelatedPartyDebts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Forgivness of related party debt" } } }, "localname": "ForgivenessOfRelatedPartyDebts", "nsuri": "http://healthrevenue.com/20220331", "presentation": [ "http://healthrevenue.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "hraad_HolderOwnership": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Holder ownership" } } }, "localname": "HolderOwnership", "nsuri": "http://healthrevenue.com/20220331", "presentation": [ "http://healthrevenue.com/role/NatureOfBusinessAndGoingConcernDetailsNarrative" ], "xbrltype": "percentItemType" }, "hraad_ManagementsRepresentationOfInterimFinancialStatementsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Management\u2019s Representation of Interim Financial Statements" } } }, "localname": "ManagementsRepresentationOfInterimFinancialStatementsPolicyTextBlock", "nsuri": "http://healthrevenue.com/20220331", "presentation": [ "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "hraad_NumberOfPostsplitShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of post-split shares" } } }, "localname": "NumberOfPostsplitShares", "nsuri": "http://healthrevenue.com/20220331", "presentation": [ "http://healthrevenue.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "hraad_NumberOfPresplitShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of pre-split shares" } } }, "localname": "NumberOfPresplitShares", "nsuri": "http://healthrevenue.com/20220331", "presentation": [ "http://healthrevenue.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "hraad_ReverseSplitOfCommonStock1For20": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Reverse Split of Common Stock 1 for 20" } } }, "localname": "ReverseSplitOfCommonStock1For20", "nsuri": "http://healthrevenue.com/20220331", "presentation": [ "http://healthrevenue.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "hraad_ReverseSplitOfCommonStock1For20Shares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reverse Split of Common Stock 1 for 20, Shares" } } }, "localname": "ReverseSplitOfCommonStock1For20Shares", "nsuri": "http://healthrevenue.com/20220331", "presentation": [ "http://healthrevenue.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "hraad_SeriesAOnePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A One Preferred Stock [Member]" } } }, "localname": "SeriesAOnePreferredStockMember", "nsuri": "http://healthrevenue.com/20220331", "presentation": [ "http://healthrevenue.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "hraad_TotalRevenue": { "auth_ref": [], "calculation": { "http://healthrevenue.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Total Revenue" } } }, "localname": "TotalRevenue", "nsuri": "http://healthrevenue.com/20220331", "presentation": [ "http://healthrevenue.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "hraad_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average number of common shares outstanding - basic and diluted" } } }, "localname": "WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted", "nsuri": "http://healthrevenue.com/20220331", "presentation": [ "http://healthrevenue.com/role/StatementOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r10", "r169" ], "calculation": { "http://healthrevenue.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r45", "r46", "r47", "r127", "r128", "r129", "r148" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_Assets": { "auth_ref": [ "r7", "r42", "r71", "r74", "r79", "r85", "r91", "r92", "r93", "r95", "r96", "r97", "r98", "r99", "r100", "r102", "r103", "r139", "r143", "r150", "r167", "r169", "r185", "r190" ], "calculation": { "http://healthrevenue.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r15", "r42", "r85", "r91", "r92", "r93", "r95", "r96", "r97", "r98", "r99", "r100", "r102", "r103", "r139", "r143", "r150", "r167", "r169" ], "calculation": { "http://healthrevenue.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r2", "r44", "r68" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "NATURE OF BUSINESS AND GOING CONCERN" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/NatureOfBusinessAndGoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r6", "r169", "r200", "r201" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash [Default Label]", "verboseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r6", "r37" ], "calculation": { "http://healthrevenue.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "periodEndLabel": "Cash at end of period", "periodStartLabel": "Cash at beginning of period" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/BalanceSheets", "http://healthrevenue.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r32", "r151" ], "calculation": { "http://healthrevenue.com/role/StatementOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r19", "r187", "r193" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r87", "r88", "r89", "r90", "r204" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockConversionBasis": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Description of basis for conversion of convertible common stock.", "label": "Conversion ratio description" } } }, "localname": "CommonStockConversionBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/EquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r45", "r46", "r148" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Shares Par Value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/BalanceSheetsParenthetical", "http://healthrevenue.com/role/EquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/BalanceSheetsParenthetical", "http://healthrevenue.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/BalanceSheetsParenthetical", "http://healthrevenue.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r9", "r117" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/BalanceSheetsParenthetical", "http://healthrevenue.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r9", "r169" ], "calculation": { "http://healthrevenue.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, par value $0.001, 500,000,000 shares authorized, 3,417,302 (post-split) and 68,346,042 (pre-split) shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/NatureOfBusinessAndGoingConcernDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r17", "r43", "r94", "r96", "r97", "r101", "r102", "r103", "r162" ], "calculation": { "http://healthrevenue.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to related party" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss)" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/StatementOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r58", "r59" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Net Loss per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r24", "r25", "r26", "r45", "r46", "r47", "r49", "r54", "r56", "r60", "r86", "r117", "r118", "r127", "r128", "r129", "r136", "r137", "r148", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r195", "r196", "r197" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r23", "r130", "r131", "r132", "r133", "r134", "r135" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r33", "r39" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income taxes paid during the period" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "auth_ref": [ "r35" ], "calculation": { "http://healthrevenue.com/role/StatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.", "label": "Increase (Decrease) in Due to Related Parties", "verboseLabel": "Due to related party" } } }, "localname": "IncreaseDecreaseInDueToRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r39" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Interest paid during the period" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r14", "r42", "r85", "r150", "r169", "r186", "r192" ], "calculation": { "http://healthrevenue.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r5", "r18", "r42", "r85", "r91", "r92", "r93", "r96", "r97", "r98", "r99", "r100", "r102", "r103", "r140", "r143", "r144", "r150", "r167", "r168", "r169" ], "calculation": { "http://healthrevenue.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r32" ], "calculation": { "http://healthrevenue.com/role/StatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r32", "r34", "r36" ], "calculation": { "http://healthrevenue.com/role/StatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow from Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r21", "r22", "r26", "r28", "r36", "r42", "r48", "r50", "r51", "r52", "r53", "r55", "r56", "r57", "r71", "r73", "r75", "r78", "r80", "r85", "r91", "r92", "r93", "r96", "r97", "r98", "r99", "r100", "r102", "r103", "r149", "r150", "r188", "r194" ], "calculation": { "http://healthrevenue.com/role/StatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://healthrevenue.com/role/StatementOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net Income (Loss)", "verboseLabel": "Net Income (Loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows", "http://healthrevenue.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r16", "r43", "r163" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Notes payable-related party" } } }, "localname": "NotesPayableRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/DueToRelatedPartyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://healthrevenue.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total Operating Expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/StatementOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r8", "r104" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred A-1 Stock, Shares Par Value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/BalanceSheetsParenthetical", "http://healthrevenue.com/role/EquityDetailsNarrative", "http://healthrevenue.com/role/NatureOfBusinessAndGoingConcernDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred A-1 Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/BalanceSheetsParenthetical", "http://healthrevenue.com/role/EquityDetailsNarrative", "http://healthrevenue.com/role/NatureOfBusinessAndGoingConcernDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r8", "r104" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred A-1 Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/BalanceSheetsParenthetical", "http://healthrevenue.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred A-1 Stock, Shares Outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/BalanceSheetsParenthetical", "http://healthrevenue.com/role/EquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r8", "r169" ], "calculation": { "http://healthrevenue.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Series A-1 Preferred Stock, par value $0.001 25,000,000 shares authorized, 10,000,000 shares issued and outstanding at March 31, 2021 and December 31, 2021, respectively" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r202", "r203" ], "calculation": { "http://healthrevenue.com/role/StatementOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r21", "r22", "r26", "r31", "r42", "r48", "r55", "r56", "r71", "r73", "r75", "r78", "r80", "r85", "r91", "r92", "r93", "r96", "r97", "r98", "r99", "r100", "r102", "r103", "r138", "r141", "r142", "r145", "r146", "r149", "r150", "r189" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyCosts": { "auth_ref": [ "r29", "r43", "r94", "r96", "r97", "r101", "r102", "r103" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Direct costs arising from transactions with related parties who are not affiliates or joint Ventures. These costs are categorized as cost of goods sold.", "label": "Related party cost" } } }, "localname": "RelatedPartyCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/DueToRelatedPartyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r121", "r161", "r162" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/DueToRelatedPartyDetailsNarrative", "http://healthrevenue.com/role/NatureOfBusinessAndGoingConcernDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/DueToRelatedPartyDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r121", "r161", "r164", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/DueToRelatedPartyDetailsNarrative", "http://healthrevenue.com/role/NatureOfBusinessAndGoingConcernDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r159", "r160", "r162", "r165", "r166" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "DUE TO RELATED PARTY" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/DueToRelatedParty" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r11", "r118", "r169", "r191", "r198", "r199" ], "calculation": { "http://healthrevenue.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/BalanceSheets", "http://healthrevenue.com/role/NatureOfBusinessAndGoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r45", "r46", "r47", "r49", "r54", "r56", "r86", "r127", "r128", "r129", "r136", "r137", "r148", "r195", "r197" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r27", "r42", "r69", "r70", "r72", "r76", "r77", "r81", "r82", "r83", "r85", "r91", "r92", "r93", "r96", "r97", "r98", "r99", "r100", "r102", "r103", "r150", "r189" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r122", "r123", "r124", "r125", "r126" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/NatureOfBusinessAndGoingConcernDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r163", "r164" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/DueToRelatedPartyDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r30" ], "calculation": { "http://healthrevenue.com/role/StatementOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "General and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/StatementOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r35" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/EquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, Shares", "periodStartLabel": "Beginning balance, Shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r40", "r44" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r20", "r24", "r25", "r26", "r45", "r46", "r47", "r49", "r54", "r56", "r60", "r86", "r117", "r118", "r127", "r128", "r129", "r136", "r137", "r148", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r195", "r196", "r197" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r45", "r46", "r47", "r60", "r172" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r9", "r12", "r13", "r42", "r84", "r85", "r150", "r169" ], "calculation": { "http://healthrevenue.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total Stockholders\u2019 Deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/BalanceSheets", "http://healthrevenue.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r41", "r105", "r106", "r107", "r108", "r109", "r110", "r111", "r112", "r113", "r114", "r115", "r116", "r118", "r120", "r147" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Reverse stock split" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/EquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r170", "r171" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Disclosure of Interest and Income Taxes Paid:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r61", "r62", "r63", "r64", "r65", "r66", "r67" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r166": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r171": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r205": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r206": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r207": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r208": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r209": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r210": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r211": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r212": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r213": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r214": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r215": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r216": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r217": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r218": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r219": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r220": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r221": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r222": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r223": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r224": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r44": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r68": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r89": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" } }, "version": "2.1" } ZIP 34 0001829126-22-011008-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001829126-22-011008-xbrl.zip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end